Clinical Trial Update: Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial [Phase 3]

View source ↗

Summary

Phase III randomized trial comparing Hydrosorb to control for radiation-induced skin toxicity in breast cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Radiation Dermatitis

Drugs mentioned

• Hydrosorb

Snippet

Sponsor: Institut Curie | Conditions: Breast Cancer, Radiation Dermatitis | Phase 3 | Status: COMPLETED